Why the study?
Does recombinant PSGL-1 reduce in-stent restenosis in double-injured porcine coronary arteries?
Does recombinant PSGL-1 reduce in-stent restenosis in double-injured porcine coronary arteries?
Pretreatment with rPSGL-Ig reduces thrombo-inflammatory responses and in-stent restenosis in a porcine model, suggesting a potential therapeutic target to improve clinical outcomes of coronary stenting.
Answers are grounded in this paper and cite their sources.
May attenuate restenosis in porcine models; leaves open translation to human coronary stenting.
The binding of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) to platelet P-selectin is central to post-angioplasty restenosis. Although intracoronary stents limit the mechanical component of restenosis, they cause marked thrombo-inflammation and neointimal proliferation leading to greater late luminal loss. We sought to demonstrate that P-selectin antagonism, using recombinant PSGL-1 (rPSGL-Ig), is effective in reducing platelet-leukocyte reactions and in-stent restenosis in double-injured porcine coronary arteries. Two weeks after initial injury by angioplasty to the coronary arteries, stents were implanted at the injury-induced lesion site, 15 min after an i.v. bolus administration of a vehicle or rPSGL-Ig (1 mg/kg). Four weeks later, adhesion of (51)Cr-platelets and (111)In-neutrophils and histomorphometric analyses were performed. In-stent residual lumen was almost 3 fold larger in rPSGL-Ig-treated arteries (3.1 +/- 0.4 mm(2)) as compared to control (1.1 +/- 0.2 mm(2)), which correspond to 64% vascular stenosis in control with no change in rPSGL-Ig animals. For a similar injury score, in-stent neointima was significantly reduced by 30 to 40% in the rPSGL-Ig group and quantitative coronary angiography showed a significant 35% reduction in late lumen loss. These effects of rPSGL-Ig were associated with a respective 70% and 53% reduction in platelet and neutrophil adhesion. In conclusion, pretreatment with rPSGL-Ig reduces thrombo-inflammatory responses, neointimal proliferation, and in-stent restenosis. P-selectin antagonism offers a promising therapy to improve clinical outcomes of coronary stenting.
No takes yet. Share an insight, caveat, or question.
Tanguay et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: